UnknownNCT03468296
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
PHASE4 · 22 planned enrolment
- Countries listed
- 1
- Registry update
- April 20, 2018
Registry Intervention View
Intravitreal Aflibercept Injection 2mg
Trial registrations containing the exact intervention label Intravitreal Aflibercept Injection 2mg.
Exact registry label · Not reported
2 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
1 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT00964795
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
PHASE3 · 323 planned enrolment
- Countries listed
- 2
- Registry update
- March 23, 2015